Thomas Charles Reilly - Feb 25, 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Role
Chief Financial Officer
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
CARA
Transactions as of
Feb 25, 2022
Transactions value $
$54,877
Form type
4
Date filed
3/1/2022, 03:18 PM
Previous filing
Dec 21, 2021
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Award $0 +20K +137.72% $0.00 34.5K Feb 25, 2022 Direct F1
transaction CARA Common Stock Award $54.9K +5.33K +15.45% $10.29 39.9K Feb 28, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARA Employee Stock Option (Right to Buy) Award $0 +40K $0.00 40K Feb 25, 2022 Common Stock 40K $10.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.
F2 Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 28, 2022. The vested shares represents the last of three possible vesting events of the total number of shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F3 The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.